HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.

被引：0

作者：

Brown, Jason

Kaimakliotis, Hristos Z.

Kelly, William Kevin

Ammons, Vikki

Picus, Joel

Walling, Radhika

Hashemi-Sadraei, Neda

Fu, Pingfu

Margevicius, Seunghee P.

Adra, Nabil

Garcia, Jorge A.

McKay, Rana R.

Hoimes, Christopher J.

机构：

[1] Univ Hosp Seidman Canc Ctr, Div Oncol, Cleveland, OH USA

[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[3] Thomas Jefferson Univ, Dept Med Oncol & Urol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA

[4] Virginia Oncol Associates, Norfolk, VA USA

[5] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

[6] Community Hosp Oncol Phys, Indianapolis, IN USA

[7] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87131 USA

[8] Case Western Reserve Univ, Cleveland, OH 44106 USA

[9] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[10] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA

[11] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[12] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：1

共 39 条

[21] Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3
Serizawa, Akiko
Kuramochi, Hidekazu
Taniguchi, Kiyoaki
Ota, Masaho
Katagiri, Satoshi
Yamada, Takuji
Kotake, Sho
Ito, Shunichi
Suzuki, Kazuomi
Yamamoto, Masakazu
MEDICAL ONCOLOGY, 2021, 38 (09)
[22] Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.
Matsuda, Naoko
Wang, Xiaoping
Krishnamurthy, Savitri
Alvarez, Ricardo H.
Willey, Jie S.
Lim, Bora
Parker, Charla A.
Babiera, Gildy
Booser, Daniel J.
Murray, James L.
Arun, Banu
Brewster, Abenaa M.
Reuben, James M.
Stauder, Michael Charles
Woodward, Wendy A.
Lucci, Anthony
DeSnyder, Sarah Marie
Tripathy, Debu
Valero, Vicente
Ueno, Naoto T.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
Matsuda, Naoko
Alvarez, Ricardo H.
Krishnamurthy, Savitri
Willey, Jie S.
Wang, Xiaoping
Lim, Bora
Parker, Charla A.
Marx, Angela
Babiera, Gildy
Booser, Daniel J.
Murray, James L.
Arun, Banu
Brewster, Abenaa M.
Reuben, James M.
Woodward, Wendy A.
Lucci, Anthony
Gainer, Sarah Marie
Tripathy, Debu
Valero, Vicente
Ueno, Naoto T.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] Neoadjuvant chemotherapy and radiation with intensity modulated radiation therapy (IMRT) in a dose escalation phase II study for patients with T4 recto sigmoid cancer
Vuong, T
Portelance, L
Ru, R
Dalfen, R
Meterissian, S
Stein, B
Gouttbel, MC
Wexler, M
RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S3 - S3
[25] Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
Tamura, Kenji
Hashimoto, Jun
Tsuda, Hitoshi
Yoshida, Masayuki
Yamauchi, Hideko
Aogi, Kenjiro
Shimizu, Satoru
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Inoue, Kenichi
Ohno, Shinji
Kuroi, Katsumasa
Sukigara, Tamie
Fujiwara, Yasuhiro
Andoh, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC)
Fishman, Mayer N.
Vaena, Daniel A.
Singh, Parminder
Picus, Joel
Vaishampayan, Ulka N.
Slaton, Joel
Mahoney, John Francis
Agarwala, Sanjiv S.
Rosser, Charles Joel
Landau, Danny
Hajdenberg, Julio
Van Veldhuizen, Peter J.
Parikh, Rahul Atul
Alter, Sarah
Hernandez, Liza
Rhode, Peter
Wong, Hing C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[27] Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.
Dang, Chau T.
Gianni, Luca
Romieu, Gilles
Dirix, Luc
Campone, Mario
Citron, Marc L.
Zamagni, Claudio
Krop, Ian E.
Xu, Na
Smitt, Melanie
Suter, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[28] Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.
Guarneri, V.
Frassoldati, A.
Ficarra, G.
Maiorana, A.
Bettelli, S.
Bottini, A.
Cagossi, K.
Bisagni, G.
Ravaioli, A.
Amadori, D.
Musolino, A.
Cavanna, L.
Orlando, L.
Giardina, G.
Piacentini, F.
Bagnalasta, M.
Conte, P.
CANCER RESEARCH, 2011, 71
[29] Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) plus /- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
Leary, A.
Rouge, T. De La Motte
Lortholary, A.
Asselain, B.
Alexandre, J.
Floquet, A.
Savoye, A. M.
Chardin, L.
Delanoy, N.
Gavoille, C.
You, B.
D'Hondt, V.
Grenier, J.
Genestie, C.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2021, 32 : S731 - S731
[30] A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti-immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer
Lee, Jung-Yun
Bell, Maria
Bidzinski, Mariusz
Bodnar, Lubomir
Chan, Jack Junjie
Gill-Martin, Marta
Ibanez, Carolina
Lorusso, Domenica
Lu, Chien-Hsing
Rosengarten, Ora
Townson, Steven M.
Kobie, Julie
Zhang, Yiwei
Pruitt, Scott
Shapira-Frommer, Ronnie
CANCER RESEARCH, 2023, 83 (08)

← 1 2 3 4 →